NDAOPHTHALMICEMULSION
Approved
Sep 2018
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
5/8 — Partial
XELPROS (latanoprost) by Fosun Pharma is 2α analogue that is believed to reduce the iop by increasing the outflow of aqueous humor. First approved in 2018.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XELPROS is a latanoprost ophthalmic emulsion approved in 2018 for reducing intraocular pressure (IOP) in glaucoma and ocular hypertension patients. It is a prostaglandin F2α analogue that works by increasing uveoscleral aqueous humor outflow, thereby lowering IOP and reducing the risk of optic nerve damage and visual field loss.
$0.004BPart D
Peak2.9 years to LOEProduct is in peak lifecycle stage with modest Medicare spending; team size likely stable with focus on market consolidation rather than growth expansion.
Mechanism of Action
2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the…
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
Started Jul 2026
50 enrolled
Ocular HypertensionSuspect Glaucoma
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Started Nov 2025
30 enrolled
Open Angle GlaucomaOcular Hypertension
A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension
Started May 2022
0Ocular Hypertension
Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension.
Started Mar 2022
1 enrolled
Open Angle GlaucomaOcular Hypertension
Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells
Started Sep 2021
Worked on XELPROS at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.